INSM2 inhibitors are part of a chemical class that targets the INSM2 (insulinoma-associated 2) protein, a protein involved in cellular processes in various organisms. INSM2, though named for its association with insulinoma, has broad implications in the world of cellular biology. The name "inhibitor" typically suggests that the chemicals or molecules in this class hinder or reduce the activity or the function of the protein they target. In the case of INSM2 inhibitors, they are designed to interact and modulate the activity or expression of INSM2, which can influence the downstream cellular events linked to this protein.
The structure and specific mechanism of action of INSM2 inhibitors can vary widely, as is common with many classes of chemicals or drugs. These inhibitors may be small organic molecules, peptides, or even larger biomolecules. Their method of action might involve direct binding to the INSM2 protein, blocking it from fulfilling its normal cellular function. Alternatively, they might operate indirectly, by influencing pathways or other proteins that, in turn, regulate INSM2 activity. Understanding the specifics of these inhibitors, including their physicochemical properties, molecular interactions, and off-target effects, is essential for researchers in fields that study INSM2 and its associated cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
Targets tyrosine kinases, especially BCR-ABL in leukemia. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Stabilizes microtubules, disrupting cell division. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, including VEGFR and RAF. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Blocks estrogen receptors in breast cancer cells. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Inhibits dihydrofolate reductase, disrupting DNA synthesis. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Targets EGFR and HER2 kinases in breast cancer. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Blocks EGFR kinase activity in non-small cell lung cancer. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Inhibits proteasome, leading to cell cycle arrest. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Selectively targets mutated BRAF in melanoma. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Inhibits multiple kinases, including BCR-ABL and SRC. | ||||||